Skip to main content
SpringerLink
Log in

Low-Dose Aspirin in the Cardiovascular System

  • Chapter
  • First Online:
NSAIDs and Aspirin

  • 2141 Accesses

Abstract

This chapter highlights practical aspects related to aspirin therapy in cardiovascular diseases, specifically, the benefits and hazards in different clinical settings. The absolute benefit of aspirin is linearly related to the risk of the patient. The benefit of aspirin can vary substantially in different settings. For example, in primary prevention in low-risk population, it is not unusual that the number of vascular events avoided equals the number of major bleeds induced by aspirin. In the secondary prevention, the benefits usually outweigh the excess of major bleeding complications. In this setting, the assessment of both bleeding risk and cardiovascular benefits of low-dose aspirin for any individual patient may be difficult in clinical practice. On the other hand, the relatively rare occurrence of major bleeding (gastrointestinal or cerebrovascular) complications should not be underestimated, mainly due to its high morbi-mortality. For all these reasons, in this chapter new developments in the field directed toward individualized risk assessment strategies are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. World Health Organization. [homepage on the Internet]. http://www.who.int/en/, last accessed in January 2016.

  2. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:49–59.

    Article  Google Scholar 

  3. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988;296:313–6.

    Article  CAS  Google Scholar 

  4. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med. 1989;321(3):129–35.

    Google Scholar 

  5. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework. Lancet 1998; 351:233–41.

    Google Scholar 

  6. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755–62.

    Article  CAS  PubMed  Google Scholar 

  7. de Gaetano G, Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001;357(9250):89-95.

    Google Scholar 

  8. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low- dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293–304.

    Article  CAS  PubMed  Google Scholar 

  9. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.

    Google Scholar 

  10. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300(18):2134–41.

    Article  CAS  PubMed  Google Scholar 

  11. Fowkes FR, Price JF, Stewart MW, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303(9):841–8.

    Article  CAS  PubMed  Google Scholar 

  12. García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011;123(10):1108–15.

    Article  PubMed  Google Scholar 

  13. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–60.

    Article  Google Scholar 

  14. Patrono C, Baigent C, Hirsh J, Roth G, American College of Chest Physicians. Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed.). Chest. 2008;133(6 Suppl):199S–233S.

    Article  CAS  PubMed  Google Scholar 

  15. Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, Wang K, Zou Y, Ge J. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes Res Clin Pract. 2010;87:211–8.

    Article  CAS  PubMed  Google Scholar 

  16. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation. 2010;121:2694–701.

    Article  PubMed  Google Scholar 

  17. Nelson M, Reid C, Beilin L, Donnan G, Johnston C, Krum H. Aspirin in Reducing Events in the Elderly (ASPREE) Study Group. Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE). Drugs Aging. 2003;20(12):897–903.

    Article  CAS  PubMed  Google Scholar 

  18. De Berardis G, Sacco M, Evangelista V, ACCEPT-D Study Group, et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials. 2007;8:21.

    Article  PubMed  PubMed Central  Google Scholar 

  19. ASPREE Investigator Group. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials. 2013;36(2):555–64.

    Article  PubMed Central  Google Scholar 

  20. ARRIVE Study Website. Aspirin to Reduce Risk of Initial Vascular Events (ARRIVE). Bayer HealthCare. Available at: http://www.arrive-study.com/EN/study.cfm. Accessed January 10, 2016.

  21. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349–60.

    Google Scholar 

  22. Patrono C1, Andreotti F, Arnesen H, Badimon L, Baigent C, Collet JP, De Caterina R, Gulba D, Huber K, Husted S, Kristensen SD, Morais J, Neumann FJ, Rasmussen LH, Siegbahn A, Steg PG, Storey RF, Van de Werf F, Verheugt F. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J. 2011;32(23):2922–32.

    Google Scholar 

  23. Steering Committee CAPRIE. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329–39.

    Article  Google Scholar 

  24. Lewis Jr HD, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983;309(7):396–403.

    Article  PubMed  Google Scholar 

  25. Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med. 1985;313(22):1369–75.

    Article  CAS  PubMed  Google Scholar 

  26. Van de Werf F, Bax J, Betriu A, Blomstrom Lundqvist C, Crea F, Falk V. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29(23):2909–45.

    Article  PubMed  Google Scholar 

  27. Goff Jr DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2935–59.

    Article  PubMed  Google Scholar 

  28. Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(12):3754–832.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Preventive Services Task Force US. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150:396–404.

    Article  Google Scholar 

  30. Bibbins-Domingo K, U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016;164(12):836–45.

    Google Scholar 

  31. European Guidelines on cardiovascular disease prevention in clinical practice (version2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).Eur J Prev Cardiol 2012; 19(4): 585-667.

    Google Scholar 

  32. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):2354–9.

    Article  PubMed  Google Scholar 

  33. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation. Rev Esp Cardiol. 2015;68(12):1125.

    Article  PubMed  Google Scholar 

  34. Tanguay JF, Bell AD, Ackman ML, et al. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of anti- platelet therapy. Can J Cardiol. 2013;29(11):1334–45.

    Article  PubMed  Google Scholar 

  35. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: a meta-analysis on 376,162 patients. Am J Med 2012; 125: 882–7.e1.

    Google Scholar 

  36. Vanwormer JJ, Greenlee RT, McBride PE. Aspirin for primary prevention of CVD: are the right people using it? J Fam Pract. 2012;61:525–33.

    Google Scholar 

  37. de Groot NL, van Haalen HG, Spiegel BM, Laine L, Lanas A, Focks JJ, Siersema PD, van Oijen MG. Gastroprotection in low-dose aspirin users for primary and secondary prevention of ACS: results of a cost-effectiveness analysis including compliance. Cardiovasc Drugs Ther. 2013;27(4):341–57.

    Article  CAS  PubMed  Google Scholar 

  38. You JJ, Singer DE, Howard PA, et al. American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e531S–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.

    Article  PubMed  Google Scholar 

  40. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–17.

    Article  CAS  PubMed  Google Scholar 

  41. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014:2;64(21):e1–76.

    Google Scholar 

  42. Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol. 2008;28(3):370–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, Bianchi M, Moia M, Ageno W, Vandelli MR, Grandone E, Prandoni P. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366(21):1959–67.

    Article  CAS  PubMed  Google Scholar 

  44. Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, Gibbs H, Hague W, Xavier D, Diaz R, Kirby A, Simes J. Low-dose aspirin for preventing re- current venous thromboembolism. N Engl J Med. 2012;367(21):1979–87.

    Article  CAS  PubMed  Google Scholar 

  45. Lanas A, Polo-Tomás M, Casado-Arroyo R. The aspirin cardiovascular/gastrointestinal risk calculator--a tool to aid clinicians in practice. Aliment Pharmacol Ther. 2013;37(7):738–48.

    Article  CAS  PubMed  Google Scholar 

  46. Teramoto T, Shimada K, Uchiyama S, et al. Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomised, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events. Am Heart J. 2010;159:361–9. e4.

    Article  CAS  PubMed  Google Scholar 

  47. Reid CM, Storey E, Wong TY, et al. Aspirin for the prevention of cognitive decline in the elderly: rationale and design of a neuro-vascular imaging study (ENVIS-ion). BMC Neurol. 2012;12:3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgment

This review was funded by a grant for international research, Foundation Horlait-Dapsens (RC).

Author information

Authors and Affiliations

  1. Department of Cardiology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium

    Ruben Casado-Arroyo M.D., Ph.D.

  2. Universidad de Zaragoza, IIS Aragón, CIBER Enfermedades HepÃticas y Digestivas (CIBERehd), Zaragoza, Spain

    Angel Lanas M.D., Ph.D., A.G.A.F., A.C.G.F.

  3. Service of Digestive Diseases, University Hospital Lozano Blesa, Zaragoza, Spain

    Angel Lanas M.D., Ph.D., A.G.A.F., A.C.G.F.

  4. Cardiovascular Division, Heart Rhythm Management Center, Cardiovascular Center, Free University of Brussels (UZ Brussels) VUB, Brussels, Belgium

    Pedro Brugada M.D., Ph.D.

Authors
  1. Ruben Casado-Arroyo M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Angel Lanas M.D., Ph.D., A.G.A.F., A.C.G.F.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pedro Brugada M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ruben Casado-Arroyo M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. IIS Aragón, CIBER Enfermedades Hepáicas y Digestivas (CIBERehd), Universidad de Zaragoza, Zaragoza, Spain

    Angel Lanas

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Casado-Arroyo, R., Lanas, A., Brugada, P. (2016). Low-Dose Aspirin in the Cardiovascular System. In: Lanas, A. (eds) NSAIDs and Aspirin. Springer, Cham. https://doi.org/10.1007/978-3-319-33889-7_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-33889-7_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-33887-3

  • Online ISBN: 978-3-319-33889-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation